Twist Bioscience Corp (TWST) is a revolutionary biotechnology company that focuses on the development and commercialization of disruptive synthetic DNA technologies. Its groundbreaking synthetic DNA technologies and strategies can be utilized in various ways, such as to produce potent genetic drugs, disease prevention strategies, and even improving food crop yield.
The company, listed on NASDAQ, was founded in 2013 in San Francisco, California, United States, with its main corporate objective being to create sustainable and scalable solutions for breakthroughs in health, sustainability, and other areas relevant to life.
Twist Bioscience Corp creates synthetic DNA by writing it onto a silicon chip. This process enables the cost-effective and rapid production of synthetic DNA sequences. Subsequently, the synthesized DNA is utilized to formulate data solutions and DNAs for the research concerning a wide range of industries such as pharmaceuticals, biotech, industrial chemicals, and data storage.
The company offers high-quality synthetic DNA and RNA products for clinical research. Its advanced drug discovery techniques include target discovery, validation, assay development, and optimization. They also provide biopharma products including antibodies to facilitate better understanding of diseases, and discovery of effective treatments.
Additionally, Twist Bioscience Corp also caters to the industrial biotechnology industry with their bio-based chemicals which are sustainable alternatives to petroleum-based products. They focus on producing high-performance bioplastics and biofuels that are better for the environment.
A notable development in their data storage segment is the DNA data storage, which is an innovative technology that utilizes DNA to store digital data. This method could potentially offer more compact storage methods and longer lifespans than traditional storage solutions.
Twist Biosciences Corp. is led by CEO and co-founder Emily Leproust, Ph.D., a well-respected industry veteran who previously worked as a director at Agilent Technologies and holds over 50 patents. Under her leadership, the company emphasizes a culture of scientific rigor and integrity and aims to disrupt the status quo in biotechnology and foster innovation in DNA synthesis.
The company’s mission is to provide synthetic DNA products and solutions that accelerate advancements in health and sustainability. Through its cutting-edge technologies, Twist Bioscience is transforming industries and pushing the boundaries of what is possible in biotechnology. Despite being a relatively young company, it has positioned itself as a significant player in its field thanks to its progressive, forward-thinking approach and commitment to scientific integrity and innovation.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Twist Bioscience Corporation's stock surged 16.1% to $184.03, driven by a partnership with Lilly TuneLab, pushing it into overbought territory with daily RSI at 74.39. While the trend is strongly bullish across all timeframes, indicators suggest overextension and potential for a pullback, necessitating cautious risk management. Key support levels are identified at $175.36 and $165.50, with analysts' price targets currently below the trading price.
Twist Bioscience (TWST) stock surged 16% after Leerink Partners raised its price target, citing the company as a key beneficiary of Anthropic's expanding biology research. Leerink highlighted Anthropic's use of Twist Bioscience's synthetic DNA for protein design testing, with Claude analyzing lab data rapidly. This move, along with a recent deal with Eli Lilly, positions Twist Bioscience as critical infrastructure for AI drug discovery, outperforming market expectations and analyst price targets.
Twist Bioscience Corp (TWST) saw an 11.04% stock increase on September 24, driven by a strategic collaboration with Eli Lilly, integrating Twist's data services into Lilly's AI-driven drug discovery platform. This partnership, coupled with strong third-quarter financial results showing double-digit revenue growth and improved margins, has generated significant investor interest and positive analyst sentiment. Despite this growth, the company faces risks such as persistent net losses, a high valuation, and recent insider share liquidations.
Twist Bioscience (TWST) shares fell 3.8% due to profit-taking after a recent rally and news of CEO Emily Leproust's planned share sale. Despite no negative operational updates, the stock's valuation near its 52-week high made it susceptible to a pullback. The decline follows a strong rally driven by a new partnership with Lilly TuneLab announced on September 16.
Twist Bioscience (TWST) has partnered with Lilly TuneLab, a platform by Eli Lilly and Company (LLY), to provide antibody characterization data services for AI-driven drug discovery. This collaboration positions Twist to benefit from the growing AI drug discovery ecosystem by supplying high-quality experimental data and services. While the partnership strengthens Twist's exposure to AI in drug development, the near-term financial impact is uncertain as no specific revenue commitments have been disclosed.